Cost‐Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States

by Odette S. Reifsnider, Ali Tafazzoli, Stephan Linden, Jack Ishak, Pal Rakonczai, Matthew Stargardter, Effie Kuti
Published 2024-02-01

Simulated estimates of pre-pregnancy and gestational diabetes mellitus in the US: 1980 to 2008.

by Maria E Mayorga, Odette S Reifsnider, David M Neyens, Mulugeta G Gebregziabher, Kelly J Hunt
Published 2013-01-01

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease

by Odette S Reifsnider, Anuraag R Kansal, Pranav K Gandhi, Lael Cragin, Sarah B Brand, Egon Pfarr, Kyle Fahrbach, Anastasia Ustyugova
Published 2021-08-01

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia

by Anuraag R. Kansal, Odette S. Reifsnider, Sarah B. Brand, Neil Hawkins, Anna Coughlan, Shujun Li, Lael Cragin, Clark Paramore, Andrew C. Dietz, J. Jaime Caro
Published 2021-01-01

Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure

by Odette S. Reifsnider, Anuraag R. Kansal, Jennifer Franke, Joseph Lee, Jyothis T. George, Martina Brueckmann, Stefan Kaspers, Sarah B. Brand, Anastasia Ustyugova, Stephan Linden, Matthew Stargardter, Nikco Hau
Published 2020-12-01